Published on:

Experts state that new Merck drug will not get FDA approval

Two prominent U.S. heart experts recently stated that studies of Merck’s new arthritis drug Arcoxia revealed risks that should prevent its FDA approval. Further, the drug has posed unacceptable dangers in the 63 countries where it is currently sold. The doctors stated in interviews that they were concerned that patients taking Arcoxia in a large international trial had a higher incidence of edema, elevated blood pressure, and congestive heart failure than patients taking the standard treatment diclofenac.

For the full article.